The effectiveness of the clinical pathways for children hospitalized for the treatment of acute asthma exacerbation.

IF 1 4区医学 Q3 PEDIATRICS

Pediatrics International Pub Date : 2025-01-01 DOI:10.1111/ped.70073

Riko Kanda, Masaru Kawamura, Masumi Kojiro, Yoshihisa Fujino, Takayuki Hoshina

{"title":"The effectiveness of the clinical pathways for children hospitalized for the treatment of acute asthma exacerbation.","authors":"Riko Kanda, Masaru Kawamura, Masumi Kojiro, Yoshihisa Fujino, Takayuki Hoshina","doi":"10.1111/ped.70073","DOIUrl":null,"url":null,"abstract":"Background: Guidelines for the treatment of bronchial asthma (BA) include several corticosteroids recommended for the treatment of children with acute asthma exacerbation. Clinical pathways (CPs) may contribute to the standardization of the treatment of acute asthma exacerbation and the reduction of treatment-related incidents. We investigated the effectiveness of CPs in children with acute asthma exacerbation.Methods: This retrospective study included children hospitalized for acute asthma exacerbation from August 2015 to June 2021. The patients were divided into two groups: before (pre-CP, n = 236) and after (post-CP, n = 198) the introduction of CPs for the treatment of acute asthma exacerbation. We compared the outcomes, including the length of hospital stay, types of corticosteroids used, and use of an antimicrobial agent, between the two groups.Results: Most patients in the post-CP group were treated with prednisolone or methylprednisolone, whereas several corticosteroids were administered during the pre-CP period. The proportion of patients treated with antimicrobial agents was lower in the post-CP group than in the pre-CP group (p < 0.001). The length of hospital stay was shorter in the post-CP group than in the pre-CP group (p < 0.001). The re-admission rates were similar between the two groups. No treatment-related incidents occurred during the investigation period.Conclusion: For the treatment of acute asthma exacerbation in children, the introduction of CP was useful for standardizing therapies, reducing inappropriate antimicrobial therapy, and shortening the length of hospital stay.","PeriodicalId":20039,"journal":{"name":"Pediatrics International","volume":"67 1","pages":"e70073"},"PeriodicalIF":1.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatrics International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ped.70073","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Guidelines for the treatment of bronchial asthma (BA) include several corticosteroids recommended for the treatment of children with acute asthma exacerbation. Clinical pathways (CPs) may contribute to the standardization of the treatment of acute asthma exacerbation and the reduction of treatment-related incidents. We investigated the effectiveness of CPs in children with acute asthma exacerbation.

Methods: This retrospective study included children hospitalized for acute asthma exacerbation from August 2015 to June 2021. The patients were divided into two groups: before (pre-CP, n = 236) and after (post-CP, n = 198) the introduction of CPs for the treatment of acute asthma exacerbation. We compared the outcomes, including the length of hospital stay, types of corticosteroids used, and use of an antimicrobial agent, between the two groups.

Results: Most patients in the post-CP group were treated with prednisolone or methylprednisolone, whereas several corticosteroids were administered during the pre-CP period. The proportion of patients treated with antimicrobial agents was lower in the post-CP group than in the pre-CP group (p < 0.001). The length of hospital stay was shorter in the post-CP group than in the pre-CP group (p < 0.001). The re-admission rates were similar between the two groups. No treatment-related incidents occurred during the investigation period.

Conclusion: For the treatment of acute asthma exacerbation in children, the introduction of CP was useful for standardizing therapies, reducing inappropriate antimicrobial therapy, and shortening the length of hospital stay.

查看原文本刊更多论文

儿童住院治疗急性哮喘加重的临床路径的有效性。

背景：支气管哮喘（BA）治疗指南包括几种推荐用于治疗儿童急性哮喘加重的皮质类固醇。临床路径（CPs）可能有助于急性哮喘加重治疗的标准化和治疗相关事件的减少。我们调查了CPs在儿童急性哮喘加重中的有效性。方法：本回顾性研究纳入2015年8月至2021年6月因急性哮喘加重住院的儿童。患者分为两组：采用cp治疗急性哮喘加重前（n = 236）和采用cp治疗急性哮喘加重后（n = 198）。我们比较了两组之间的结果，包括住院时间、使用的皮质类固醇类型和抗菌药物的使用。结果：cp后组大多数患者使用强的松龙或甲基强的松龙治疗，而cp前组使用几种皮质类固醇。CP后组使用抗菌药物的患者比例低于CP前组(p)结论：CP的引入有助于规范治疗，减少不适当的抗菌药物治疗，缩短住院时间。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatrics International 医学-小儿科

CiteScore

2.00

自引率

7.10%

发文量

519

审稿时长

12 months

期刊介绍： Publishing articles of scientific excellence in pediatrics and child health delivery, Pediatrics International aims to encourage those involved in the research, practice and delivery of child health to share their experiences, ideas and achievements. Formerly Acta Paediatrica Japonica, the change in name in 1999 to Pediatrics International, reflects the Journal''s international status both in readership and contributions (approximately 45% of articles published are from non-Japanese authors). The Editors continue their strong commitment to the sharing of scientific information for the benefit of children everywhere. Pediatrics International opens the door to all authors throughout the world. Manuscripts are judged by two experts solely upon the basis of their contribution of original data, original ideas and their presentation.